In 2008 was created Ares Life Sciences, which is appeared as VC. The main department of described VC is located in the Geneva. The venture was found in Europe in Switzerland.
The top amount of exits for fund were in 2006. The fund is constantly included in less than 2 investment rounds annually. The usual things for fund are deals in the range of 10 - 50 millions dollars. The top activity for fund was in 2008.
The usual cause for the fund is to invest in rounds with 5 partakers. Despite the Ares Life Sciences, startups are often financed by NGN Capital, Menlo Ventures, HBM Healthcare Investments AG. The meaningful sponsors for the fund in investment in the same round are SightLine Partners, Saints Capital, Pac-Link. In the next rounds fund is usually obtained by YA Global Master SPV, Qiming Venture Partners, Intuitive Surgical.
Among the most popular portfolio startups of the fund, we may highlight Broncus Technologies, Santhera Pharmaceuticals. We can highlight the next thriving fund investment areas, such as Health Care, Pharmaceutical. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund.
Funds with similar focus
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.